期刊
CLINICAL PHARMACOLOGY & THERAPEUTICS
卷 93, 期 3, 页码 252-259出版社
WILEY
DOI: 10.1038/clpt.2012.237
关键词
-
资金
- Cancer Research UK [C309/A8725]
- Cancer Research UK through the Stratified Medicine Programme [C21807/A13641]
- National Institute of Health Research
- Cancer Research UK [11566] Funding Source: researchfish
The progressive elucidation of the molecular pathogenesis of cancer has fueled the rational development of targeted drugs for patient populations stratified by genetic characteristics. Here we discuss general challenges relating to molecular diagnostics and describe predictive biomarkers for personalized cancer medicine. We also highlight resistance mechanisms for epidermal growth factor receptor (EGFR) kinase inhibitors in lung cancer. We envisage a future requiring the use of longitudinal genome sequencing and other omics technologies alongside combinatorial treatment to overcome cellular and molecular heterogeneity and prevent resistance caused by clonal evolution.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据